Akero Therapeutics is a leading cardio-metabolic biotechnology company based in South San Francisco. Specializing in the development of innovative treatments for non-alcoholic steatohepatitis (NASH), the company is dedicated to transforming the landscape of NASH therapy.
With a focus on pioneering solutions for NASH, Akero Therapeutics is at the forefront of cutting-edge research and development in the field of cardio-metabolic disorders. Committed to addressing the unmet medical needs of patients, the company's transformative approach holds promise for those affected by NASH.
Generated from their website's infomation